Binetrakin
Alternative Names: Interleukin-4 - DNAX; Quadrakine; SCH 39400Latest Information Update: 20 Aug 2009
Price :
$50 *
At a glance
- Originator Schering-Plough
- Developer Nonindustrial sources; Schering-Plough
- Class Interleukins
- Mechanism of Action B cell stimulants; Interleukin 1 beta inhibitors; Interleukin 4 receptor agonists; Interleukin 6 receptor antagonists; Interleukin 8 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal cancer; Immunodeficiency disorders; Inflammation; Kaposi's sarcoma; Malignant melanoma; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Psoriasis; Rheumatoid arthritis; Solid tumours
Most Recent Events
- 20 Aug 2009 Discontinued - Clinical-Phase-Unknown for Psoriasis in Netherlands (SC)
- 26 May 2003 Clinical trials in Psoriasis in Germany (SC)
- 26 May 2003 Clinical trials in Psoriasis in Netherlands (SC)